Exergen Corporation Awarded New Patent for Inflammation Detection to Aid Diabetes Patients

Watertown, MA, May 30, 2024 – Exergen Corporation, a leader in infrared temperature measurement technologies, announced today that it has been granted a new patent for innovative devices and methods aimed at detecting inflammation, specifically designed to help diabetes patients monitor their health. The patent, titled “Devices and Methods for Detecting Inflammation,” represents a significant advancement in non-invasive medical diagnostics.

Highly accurate temperature measurements in clinical settings

Since the 1980s, Exergen and its founder, Dr. Frank Pompei, have profoundly impacted the field of medical temperature measurement. The company has pioneered various technologies and holds numerous patents that have revolutionized how temperature is monitored in clinical settings. Frank Pompei’s innovative vision has consistently driven Exergen to develop solutions that enhance patient care and safety.

This latest patent introduces a method to measure the temperature of the skin on the feet of diabetes patients, providing an easy yet highly accurate way to detect inflammation. Early detection of inflammation is crucial for diabetes patients, as it can prevent severe complications such as infections or ulcers, which are common due to peripheral neuropathy. A lack of blood flow can even result in amputations.

Early detection of inflammation is crucial for diabetes patients

“Our new patented technology offers a reliable and non-invasive means for diabetes patients to take better care of themselves,” said Dr. Francesco Pompei, founder and CEO of Exergen Corporation. “By enabling early detection of inflammation, we can help prevent the progression of potentially severe conditions, improving the quality of life for millions of individuals managing diabetes.”

The patented device works by accurately measuring skin temperature, allowing for early identification of areas that may be developing inflammation. This proactive approach enables patients and healthcare providers to address potential issues before they escalate, offering a significant advantage in managing diabetes-related complications.

Exergen’s continuous dedication to innovation in medical temperature measurement is reflected in this new patent, underscoring the company’s commitment to enhancing patient care through advanced technological solutions. The company remains at the

forefront of developing groundbreaking devices that set new standards in the healthcare industry.

 

About Exergen

Exergen Corporation, headquartered in Watertown, Massachusetts, United States, is the leader in non-invasive temperature measurement technologies for industrial and medical applications, and delivers non-invasive temperature meters with higher accuracy, lower costs, less process control, and higher reliability than previously possible. Known in both healthcare and consumer markets for its award-winning arterial thermometer, Exergen was founded by MIT and Harvard graduate, and Harvard research scientist, Dr. Francesco Pompei, who is inventor of more than 100 patents owned by Exergen.

EXERGEN P/N: 850142, Rev 1